Kosar, A.
10/766480

FILE 'REGISTRY' ENTERED AT 08:11:58 ON 22 JUL 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8
DICTIONARY FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L1 1669 NMVPFPR|ASAFQGIGSTHWVYDGVGNS/SQSP

FILE 'CAPLUS' ENTERED AT 08:12:24 ON 22 JUL 2005

FILE COVERS 1907 - 22 Jul 2005 VOL 143 ISS 5
FILE LAST UPDATED: 21 Jul 2005 (20050721/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

L2 303 S L1

L3 9 SEA FILE=CAPLUS ABB=ON PLU=ON L2 AND ((NUTRITION? OR DIET?)(S)SUPPLEMENT? OR FOOD? OR FEED?)

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 14 Jul 2005
ACCESSION NUMBER: 2005:604480 CAPLUS
Correction of: 2005:316324
DOCUMENT NUMBER: 143:76247
Correction of: 142:371954
TITLE: Gene expression profiles and microarrays for use in diagnosis and drug screening for lung cancer
INVENTOR(S): Taylor, Ian; Pauloski, Nicole R.; Bigwood, Douglas
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032495	A2	20050414	WO 2004-US34163	20041001
WO 2005032495	C1	20050616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-508355P P 20031003

AB The present invention relates to gene expression profiles for lung cancer, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. RNA from 10 human lung tumors and from normal adjacent tissue was analyzed using Affymetrix GeneChip hybridization and 200 tumor marker genes for lung cancer are identified. The invention also provides methods and compns. for diagnostic assays for detecting cancer and therapeutic methods and compns. for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer.

IT **855561-06-7**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profiles and microarrays for use in diagnosis and drug screening for lung cancer)

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 11 Mar 2005
ACCESSION NUMBER: 2005:216606 CAPLUS
DOCUMENT NUMBER: 142:292452
TITLE: Compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on differential gene or protein expression
INVENTOR(S): Pasricha, Pankaj; Shenoy, Mohan; Winston, John
PATENT ASSIGNEE(S): Cytokine Pharmasciences, Inc., USA
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005020902	A2	20050310	WO 2004-US27356		20040823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005130189	A1	20050616	US 2004-923035		20040823
PRIORITY APPLN. INFO.:			US 2003-496716P	P	20030821

AB Compns. and methods for diagnosing and treating chronic visceral hypersensitivity (CVH) and CVH-associated disorders, such as irritable bowel syndrome, are disclosed. Genes differentially expressed in CVH tissues relative to normal tissues are identified. The genes and the gene products (i.e., the transcribed polynucleotides and polypeptides encoded by the genes) can be used as markers of CVH. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. The examples discuss the effects of acetic acid sensitization and CNI1493 treatment on the colon and S1 dorsal root ganglia in a rat model of visceral hypersensitivity. Gene expression profiles associated with these treatments are presented, and rat CVH-related genes and polypeptides are identified.

IT **847721-13-5**, β-Tubulin (human)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on gene or protein expression profiles)

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Mar 2005
ACCESSION NUMBER: 2005:182700 CAPLUS

DOCUMENT NUMBER: 142:238661
TITLE: Gene expression profile in activated CD4-positive T cells useful for the diagnosis and treatment of immune-related diseases
INVENTOR(S): Abbas, Alexander; Clark, Hilary; Ouyang, Wenjun; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019258	A2	20050303	WO 2004-US25788	20040810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005019258	A2	20050303	WO 2004-XA25788	20040810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:			
US 2003-493546P	P	20030811	
WO 2004-US25788	A	20040810	

AB The present invention relates to composition containing novel proteins and method of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4-pos. T-cells activated with an anti-CD23 and anti-CD28 antibodies together with specific cytokines provides 3232 genes that are differentially expressed in comparison to resting CD4-pos. T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **845221-36-5 845222-98-2 845224-38-6**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(amino acid sequence; gene expression profile in activated CD4-pos. T cells useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Feb 2005
ACCESSION NUMBER: 2005:158694 CAPLUS
DOCUMENT NUMBER: 142:238660
TITLE: Gene expression profile in activated CD4-positive T cells useful for the diagnosis and treatment of immune-related diseases
INVENTOR(S): Abbas, Alexander; Clark, Hilary; Ouyang, Wenjun; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016962	A2	20050224	WO 2004-US26249	20040811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005016962	A2	20050224	WO 2004-XA26249	20040811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:	US 2003-493546P	P	20030811
	WO 2004-US26249	A	20040811

AB The present invention relates to composition containing novel proteins and method of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4-pos. T-cells activated with an anti-CD23 and anti-CD28 antibodies together with

specific cytokines provides 3232 genes that are differentially expressed in comparison to resting CD4-pos. T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **845186-43-8 845188-05-8 845189-45-9**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profile in activated CD4-pos. T cells useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Jun 2004
ACCESSION NUMBER: 2004:467689 CAPLUS
DOCUMENT NUMBER: 141:37604
TITLE: Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases
INVENTOR(S): Clark, Hilary; Hunte, Bridsell; Jackman, Janet; Schoenfeld, Jill; Willians, Mickey P.; Wood, William I.; Wu, Thomas D.; Bodary, Sarah
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 8598 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047728	A2	20040610	WO 2003-US35971	20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004047728	A2	20040610	WO 2003-XA35971	20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-429069P P 20021126

WO 2003-US35971 A 20031124

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4+ T-cells activated with an anti-CD3 antibody together with either ICAM-1 or anti-CD28 antibody provides genes that are differentially expressed in comparison to resting CD4+ T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **701312-15-4P 701987-88-4P 701988-13-8P**
702715-26-2P 702718-15-8P 702718-46-5P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 May 2004
ACCESSION NUMBER: 2004:430695 CAPLUS
DOCUMENT NUMBER: 141:22225
TITLE: Gene expression profiles for activated natural killer cells and their use for diagnosis and treatment of natural killer cell-related diseases
INVENTOR(S): Fong, Sherman; Dennis, Kathryn; Clark, Hilary; Chiu, Henry; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 1731 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043361	A2	20040527	WO 2003-US35268	20031106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-425235P P 20021108

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of

immune-related diseases. Thus, specific cDNA sequences (and their encoded protein sequences) are identified which are differentially expressed in activated natural killer cells as compared to normal resting NK cells using hybridization to Affimax microarray chips and proprietary Genentech microarrays. Activation of NK cells with interleukin-12, interleukin-15, or JAM2 was monitored by FACS for cell surface expression of CD56 and CD69.

IT **696667-25-1P 696671-14-4P 696671-21-3P**
696672-44-3P 696673-43-5P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; gene expression profiles for activated natural killer cells and their use for diagnosis and treatment of natural killer cell-related diseases)

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 May 2004
ACCESSION NUMBER: 2004:412755 CAPLUS
DOCUMENT NUMBER: 141:5810
TITLE: Differentially expressed genes and encoded proteins in differentiated macrophages that are useful for diagnosis and treatment of immune-related diseases
INVENTOR(S): Clark, Hilary; Schoenfeld, Jill; Van Lookeren, Menno; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 2940 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041170	A2	20040521	WO 2003-US34312	20031030

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-423394P P 20021101

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Specific cDNA sequences are provided which are differentially expressed (up-regulated) in differentiated macrophages at day 7 as compared to normal undifferentiated monocytes at day 0 and day 1. The encoded proteins are useful not only as

diagnostic markers for the presence of one or more immune disorders, but also serve as therapeutic targets for the treatment of those immune disorders and inflammatory immune responses..

IT **694539-54-3 694543-35-6 694548-37-3 694548-48-6 694548-90-8 694551-10-5 694552-91-5**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; differentially expressed genes and encoded proteins in differentiated macrophages that are useful for diagnosis and treatment of immune-related diseases)

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 14 May 2004
ACCESSION NUMBER: 2004:392574 CAPLUS
DOCUMENT NUMBER: 140:405466
TITLE: Differentially expressed nucleic acids and their encoded proteins useful for the diagnosis and treatment of immune-related diseases
INVENTOR(S): Aggarwal, Sudeepta; Clark, Hilary; Gurney, Austin L.; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 3009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039956	A2	20040513	WO 2003-US34381	20031028

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-422472P P 20021029

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Various polypeptides of the present invention are significantly differentially expressed in isolated CD45RO cells activated by anti-CD3/anti-CD28 as compared to isolated resting CD45RO cells, isolated resting CD45RA cell, and isolated CD45RA cells activated by anti-CD3/anti-CD28 antibodies.

IT **688816-39-9 688820-97-5 688821-07-0 688822-60-8**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(amino acid sequence; differentially expressed nucleic acids and their encoded proteins useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Sep 2003
ACCESSION NUMBER: 2003:696678 CAPLUS
DOCUMENT NUMBER: 139:212906
TITLE: Human genes up-regulated by stimulation with ICAM-1 and/or anti-CD28 and their use in treatment of immune-related diseases
INVENTOR(S): Bodary, Sarah C.; Clark, Hilary; Hunte, Brisdell; Jackman, Janet K.; Schoenfeld, Jill R.; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 918 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003072035	A2	20030904	WO 2003-US5241		20030221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2476518	AA	20030904	CA 2003-2476518		20030221
US 2004258678	A1	20041223	US 2003-370715		20030221
PRIORITY APPLN. INFO.:			US 2002-359461P	P	20020222
			WO 2003-US5241	W	20030221

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune related diseases. Isolated CD4+ T cells are activated with an anti-CD3 antibody (used at a concentration that does not stimulate proliferation) together with either ICAM-1 , anti-CD28 antibody, or a combination of both ICAM-1 and anti-CD28. At 24 or 72 h the cells were harvested, RNA extracted, and anal. run on Affimax U95A chips. Three hundred seventy-one genes were identified whose expression was up-regulated at either of the two timepoints in activated vs. resting cells. These cDNA sequences and their encoded proteins may be useful in targeting inflammatory processes which are associated with ICAM-1 and/or anti-CD28 antibodies.

IT **588739-86-0**, Protein PRO66269 (human clone DNA287199)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; human genes up-regulated by stimulation with ICAM-1 and/or anti-CD28 and their use in treatment of immune-related diseases)

E50 THROUGH E80 ASSIGNED

FILE 'REGISTRY' ENTERED AT 08:15:34 ON 22 JUL 2005
L4 31 SEA FILE=REGISTRY ABB=ON PLU=ON (588739-86-0/BI OR 688816-39-9/BI OR 688820-97-5/BI OR 688821-07-0/BI OR 688822-60-8/BI OR 694539-54-3/BI OR 694543-35-6/BI OR 694548-37-3/BI OR 694548-48-6/BI OR 694548-90-8/BI OR 694551-10-5/BI OR 694552-91-5/BI OR 696667-25-1/BI OR 696671-14-4/BI OR 696671-21-3/BI OR 696672-44-3/BI OR 696673-43-5/BI OR 701312-15-4/BI OR 701987-88-4/BI OR 701988-13-8/BI OR 702715-26-2/BI OR 702718-15-8/BI OR 702718-46-5/BI OR 845186-43-8/BI OR 845188-05-8/BI OR 845189-45-9/BI OR 845221-36-5/BI OR 845222-98-2/BI OR 845224-38-6/BI OR 847721-13-5/BI OR 855561-06-7/BI)

L5 31 L1 AND L4

L5 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **855561-06-7** REGISTRY
CN INDEX NAME NOT YET ASSIGNED
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 143:76247

L5 ANSWER 2 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **847721-13-5** REGISTRY
CN β-Tubulin (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 86: PN: WO2005020902 SEQID: 63 claimed protein
CI MAN
SQL 451

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKECENCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKVREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSIH IQLVENTDET
201 YCIDNEALYD ICFRTLKLAT PTYGDLNHLV SATMSGVTTS LRFPGQLNAD
251 LRKLAVNMVP FPRLBFFMPG FAPLTARGSQ QYRALTVPEL TQQMFDAKNM
==== ===
301 MAACDPRHGR YLTVATVFRG RMSMKEVDEQ MLAIQSKNSS YFVEWIPNNV

```
       351 KVAVCDIPPR GLKMSSTFIG NSTAIQELFK RISEQFTAMF RRKAFLHWYT
       401 GEGMDEMEFT EAESNMNDLV SEYQQYQDAT AEEEGEMYED DEEESEAQGP
       451 K
HITS AT:    257-263

REFERENCE   1:  142:292452

L5   ANSWER 3 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   845224-38-6  REGISTRY
CN   Immune disease-associated protein PRO84514 (human) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   2502: PN: WO2005019258 SEQID: 2796 claimed protein
CI   MAN
SQL  450

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
        51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKECENCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKVREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSIH QLVENTDETY
       201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTRRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
       351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  142:238661

L5   ANSWER 4 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   845222-98-2  REGISTRY
CN   Immune disease-associated protein PRO10347 (human) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   2186: PN: WO2005019258 SEQID: 2426 claimed protein
CI   MAN
SQL  444

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  142:238661

L5   ANSWER 5 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   845221-36-5  REGISTRY
```

CN Immune disease-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1726: PN: WO2005019258 SEQID: 1884 claimed protein
CI MAN
SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238661

L5 ANSWER 6 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **845189-45-9** REGISTRY
CN Immune disease-associated protein PRO84514 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2502: PN: WO2005016962 SEQID: 2796 claimed protein
CI MAN
SQL 450

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKECENCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKVREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSIH QLVENTDETY
201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTRRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238660

L5 ANSWER 7 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **845188-05-8** REGISTRY
CN Immune disease-associated protein PRO10347 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2186: PN: WO2005016962 SEQID: 2426 claimed protein
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN

```
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  142:238660

L5   ANSWER 8 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   845186-43-8  REGISTRY
CN   Immune disease-associated protein PRO84407 (human) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   1726: PN: WO2005016962 SEQID: 1884 claimed protein
CI   MAN
SQL  445

SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  142:238660

L5   ANSWER 9 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   702718-46-5  REGISTRY
CN   T lymphocyte activation-associated protein PRO84407 (human) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   723: PN: WO2004047728 SEQID: 2967 claimed protein
CI   MAN
SQL  445

SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT:    256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 10 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **702718-15-8** REGISTRY
CN T lymphocyte activation-associated protein PRO84514 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 681: PN: WO2004047728 SEQID: 2925 claimed protein
CI MAN
SQL 450

```
SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
        51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKECENCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKVREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSIH QLVENTDETY
       201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTRRGSQQ YRALTVPELT QQMFDAKNMM
                 ===== ==
       301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
       351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK
HITS AT:   256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 11 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **702715-26-2** REGISTRY
CN T lymphocyte activation-associated protein PRO10347 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 333: PN: WO2004047728 SEQID: 2583 claimed protein
CI MAN
SQL 444

```
SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
                 ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT:   256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 12 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **701988-13-8** REGISTRY
CN T lymphocyte activation-associated protein PRO84413 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 642: PN: WO2004047728 SEQID: 2141 claimed protein
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKDMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 13 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **701987-88-4** REGISTRY
CN T lymphocyte activation-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 615: PN: WO2004047728 SEQID: 2114 claimed protein
CI MAN
SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATSLVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDSANMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFRK ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT: 256-262

REFERENCE 1: 141:37604

L5 ANSWER 14 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **701312-15-4** REGISTRY
CN T lymphocyte activation-associated protein PRO84275 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 680: PN: WO2004047728 SEQID: 678 claimed protein
CI MAN
SQL 444

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDAVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEFP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM

```
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEFEEEAE EEVA
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  141:37604

L5   ANSWER 15 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   696673-43-5  REGISTRY
CN   Natural killer cell activation-associated protein PRO84514 (human)
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   870: PN: WO2004043361 SEQID: 871 claimed protein
CI   MAN
SQL  450

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
        51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKECENCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKVREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSIH QLVENTDETY
       201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTRRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
       351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  141:22225

L5   ANSWER 16 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   696672-44-3  REGISTRY
CN   Natural killer cell activation-associated protein PRO 10347 (human)
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   752: PN: WO2004043361 SEQID: 751 claimed protein
CI   MAN
SQL  444

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  141:22225
```

L5 ANSWER 17 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **696671-21-3** REGISTRY
CN Natural killer cell activation-associated protein PRO84413 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 617: PN: WO2004043361 SEQID: 614 claimed protein
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKDMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:22225

L5 ANSWER 18 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **696671-14-4** REGISTRY
CN Natural killer cell activation-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 609: PN: WO2004043361 SEQID: 606 claimed protein
CI MAN
SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:22225

L5 ANSWER 19 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **696667-25-1** REGISTRY
CN Natural killer cell activation-associated protein PRO84275 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 191: PN: WO2004043361 SEQID: 189 claimed protein
CI MAN
SQL 445

```
SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDAVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEFP DRIMNTFSVV PSPKVSDTWV VEPYNATLSV HQLVENTDET
       201 YCIDNEALYD ICFRTLKLTT PTYGDLNHLV SATMSGVTTC LRFPGQLNAD
       251 LRKLAVNMVP FPRLHFFMPG FAPLTSRGSQ QYRALTVPEL TQQMFDAKNM
                ==== ===
       301 MAACDPRHGR YLTVAAVFRG RMSMKEVDEQ MLSVQSKNSS YFVEWIPNNV
       351 KTAVCDIPPR GLKMAATFIG NSTAIQELFK RISEQFTAMF RRKAFLHWYT
       401 GEGMDEMEFT EAESNMNDLV SEYQQYQDAT AEEGEFEEEA EEEVA
HITS AT:    257-263

REFERENCE   1:  141:22225

L5   ANSWER 20 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   694552-91-5  REGISTRY
CN   Immune-related disease-associated protein PRO84514 (human) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   1821: PN: WO2004041170 SEQID: 1821 claimed sequence
CI   MAN
SQL  450

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
        51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKECENCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKVREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSIH QLVENTDETY
       201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTRRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
       351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK
HITS AT:    256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  141:5810

L5   ANSWER 21 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   694551-10-5  REGISTRY
CN   Immune-related disease-associated protein PRO10347 (human) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   1631: PN: WO2004041170 SEQID: 1631 claimed sequence
CI   MAN
SQL  444

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 22 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **694548-90-8** REGISTRY
CN Immune-related disease-associated protein PRO83694 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1403: PN: WO2004041170 SEQID: 1403 claimed sequence
CI MAN
SQL 446

```
SEQ      1 MREIVHIQAG QCGNQIGTKF WEVISDEHGI DPAGGYVGDS ALQLERINVY
        51 YNESSSQKYV PRAALVDLEP GTMDSVRSGP FGQLFRPDNF IFGQTGAGNN
       101 WAKGHYTEGA ELVDAVLDVV RKECEHCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEFP DRIMNTFSVM PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDARNMM
                 ===== ==
       301 AACDPRHGRY LTVATVFRGP MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
       351 VAVCDIPPRG LKMASTFIGN STAIQELFKR ISEQFSAMFR RKAFLHWFTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA NDGEEAFEDE EEEIDG
```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 23 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **694548-48-6** REGISTRY
CN Immune-related disease-associated protein PRO84413 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1361: PN: WO2004041170 SEQID: 1361 claimed sequence
CI MAN
SQL 444

```
SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKDMM
                 ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 24 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **694548-37-3** REGISTRY
CN Immune-related disease-associated protein PRO84407 (human) (9CI) (CA

INDEX NAME)
OTHER NAMES:
CN 1350: PN: WO2004041170 SEQID: 1350 claimed sequence
CI MAN
SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 25 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **694543-35-6** REGISTRY
CN Immune-related disease-associated protein PRO81429 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 844: PN: WO2004041170 SEQID: 844 claimed sequence
CI MAN
SQL 445

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGSYHGDS DLQLERINVY
51 YNEAAGNKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKESESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVM PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 SIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDSKNMM
===== ==
301 AACDPRHGRY LTVAAIFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA DEQGEFEEEE GEDEA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 26 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **694539-54-3** REGISTRY
CN Immune-related disease-associated protein PRO84275 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 458: PN: WO2004041170 SEQID: 458 claimed sequence
CI MAN
SQL 444

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDAVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL

```
       151 LISKIREEFP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
             ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEFEEEAE EEVA
HITS AT:   256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  141:5810

L5   ANSWER 27 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   688822-60-8  REGISTRY
CN   Immune response-regulated protein (human clone WO2004039956-SEQID-930)
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   932: PN: WO2004039956 SEQID: 930 claimed protein
CI   MAN
SQL  444

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
             ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT:   256-262

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  140:405466

L5   ANSWER 28 OF 31  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   688821-07-0  REGISTRY
CN   Immune response-regulated protein (human clone WO2004039956-SEQID-773)
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   775: PN: WO2004039956 SEQID: 773 claimed protein
CI   MAN
SQL  444

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
        51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKDMM
             ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT:   256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 29 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **688820-97-5** REGISTRY
CN Immune response-regulated protein (human clone WO2004039956-SEQID-763) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 765: PN: WO2004039956 SEQID: 763 claimed protein
CI MAN
SQL 445

```
SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
HITS AT:   256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 30 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **688816-39-9** REGISTRY
CN Immune response-regulated protein (human clone WO2004039956-SEQID-304) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 304: PN: WO2004039956 SEQID: 304 claimed protein
CI MAN
SQL 444

```
SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDAVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEFP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
                ===== ==
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEFEEEAE EEVA
HITS AT:   256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 31 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN **588739-86-0** REGISTRY
CN Protein PRO66269 (human clone DNA287199) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 130: PN: WO03072035 FIGURE: 130 claimed protein

CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:212906

FILE 'MEDLINE' ENTERED AT 08:16:47 ON 22 JUL 2005

FILE 'BIOSIS' ENTERED AT 08:16:47 ON 22 JUL 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 08:16:47 ON 22 JUL 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

L6 1767 S L1

L9 11 SEA ABB=ON PLU=ON L6 AND ((NUTRITION? OR DIET?)(S)
SUPPLEMENT? OR FOOD OR FOODSTUFF OR FEED OR FEEDSTUFF)
L10 11 DUP REM L9 (0 DUPLICATES REMOVED)

L10 ANSWER 1 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2005184405 EMBASE
TITLE: Docetaxel in the management of ovarian cancer.
AUTHOR: Blagden S.P.; Kaye S.B.
CORPORATE SOURCE: Dr. S.P. Blagden, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.
sblagden@icr.ac.uk
SOURCE: Expert Review of Anticancer Therapy, (2005) Vol. 5, No. 2, pp. 203-214.
Refs: 97
ISSN: 1473-7140 CODEN: ERATBJ
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Obstetrics and Gynecology
016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050512
Last Updated on STN: 20050512
AB Standard first-line treatment for Stage IC-IV ovarian cancer is currently a platinum agent or a combination of a platinum agent with a

taxane. The use of a taxane compound in addition to single-agent platinum is increasingly preferred to platinum alone. In countries such as the UK, the taxane paclitaxel has been approved by the government for first-line use. However, it has yet to receive US **Food** and Drug Administration approval in the USA for use in this context. Typically, in countries such as the UK, patients with advanced ovarian cancer receive a combination of paclitaxel and carboplatin first line, both drugs given 3-weekly by intravenous infusion. Subsequent trials have demonstrated that the second-generation taxane docetaxel can be used as a substitute for paclitaxel; sharing many of its actions but with a different toxicity profile. However, docetaxel has not yet received approval for standard use. Here, the clinical development of docetaxel and its present and future place in the management of ovarian cancer is discussed. .COPYRGT. 2005 Future Drugs Ltd.

L10 ANSWER 2 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2004361632 EMBASE
TITLE: Quantification of Fusarium graminearum in infected wheat by species specific real-time PCR applying a TaqMan probe.
AUTHOR: Reischer G.H.; Lemmens M.; Farnleitner A.; Adler A.; Mach R.L.
CORPORATE SOURCE: R.L. Mach, Institute for Chemical Engineering, Gene Technology Group, Vienna Univ. Technol., G., Vienna, Austria. rmach@mail.zserv.tuwien.ac.at
SOURCE: Journal of Microbiological Methods, (2004) Vol. 59, No. 1, pp. 141-146.
Refs: 21
ISSN: 0167-7012 CODEN: JMIMDQ
PUBLISHER IDENT.: S 0167-7012(04)00154-X
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20040909
Last Updated on STN: 20040909

AB A new real-time PCR based method was developed for the species-specific detection, identification and quantification of Fusarium graminearum in planta. It utilizes a TaqMan hybridisation probe targeting the beta-tubulin gene and a plasmid standard. The assay is highly specific giving no product with DNA of closely related species. It is very sensitive, detecting down to five gene copies per reaction, and is able to produce reliable quantitative data over a range of six orders of magnitude. .COPYRGT. 2004 Elsevier B.V. All rights reserved.

L10 ANSWER 3 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2005060957 EMBASE
TITLE: Development of docetaxel in advanced non-small-cell lung cancer.
AUTHOR: Belani C.P.; Eckardt J.
CORPORATE SOURCE: C.P. Belani, Univ. of Pittsburgh Sch. of Medicine, Lung and Thoracic Cancer Program, Univ. of Pittsburgh Cancer Institute, Pittsburgh, PA, United States. cp@upmc.edu
SOURCE: Lung Cancer, (2004) Vol. 46, No. SUPPL. 2, pp. S3-S11.

Refs: 37
ISSN: 0169-5002 CODEN: LUCAE5
PUBLISHER IDENT.: S 0169-5002(04)80036-9
COUNTRY: Ireland
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050218
Last Updated on STN: 20050218

AB Docetaxel, a semisynthetic taxane initially developed for thetreatment of breast cancer, has a high degree of activity in lung cancer. Although the mechanisms of action of the taxanes docetaxel and paclitaxel are identical, docetaxel has almost a twofold higher binding affinity for the target site, beta tubulin. In clinical trials, individuals previously treated with paclitaxel benefited from docetaxel. Docetaxel is the standard of care in second-line therapy of advanced non-small-cell lung cancer (NSCLC) and is effective, alone and in combination, in first-line treatment of advanced NSCLC. The standard in first-line therapy of metastatic NSCLC is a platinum doublet with one of the third-generation chemotherapy agents, docetaxel, paclitaxel, gemcitabine, or vinorelbine. Each of these doublets offers similar therapeutic benefit. In a phase-III study comparing docetaxel-cisplatin and docetaxel-carboplatin with vinorelbine-cisplatin, patients treated in the two docetaxel arms had consistently improved global QoL compared to patients treated with the vinorelbine-cisplatin doublet. This landmark study led to **Food** and Drug Administration (FDA) approval of cisplatin-docetaxel for the treatment of advanced NSCLC. Nonplatinum doublets such as docetaxel-gemcitabine have also demonstrated efficacy and safety. Docetaxel has undergone extensive evaluation and is the only agent approved for use in both first- and second-line therapy of advanced NSCLC. .COPYRGT. 2004 Elsevier Science Ltd.

L10 ANSWER 4 OF 11 EMBASE on STN

ACCESSION NUMBER: 2003076519 EMBASE
TITLE: Monitoring the production of aflatoxin B(1) in wheat by measuring the concentration of nor-1 mRNA.
AUTHOR: Mayer Z.; Farber P.; Geisen R.
CORPORATE SOURCE: R. Geisen, Fed. Research Center for Nutrition, Institute of Hygiene and Toxicology, Haid-und-Neustr. 9, 76131 Karlsruhe, Hungary. rolf.geisen@uni-karlsruhe.de
SOURCE: Applied and Environmental Microbiology, (1 Feb 2003) Vol. 69, No. 2, pp. 1154-1158.
Refs: 23
ISSN: 0099-2240 CODEN: AEMIDF
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
052 Toxicology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20030306

Last Updated on STN: 20030306

AB A real-time reverse transcription-PCR system has been used to monitor the expression of an aflatoxin biosynthetic gene of Aspergillus flavus in wheat. Therefore, total RNA was isolated from infected wheat samples, reverse transcribed and subjected to real-time PCR. In parallel all samples were analyzed by high-pressure liquid chromatography for aflatoxin B(1) production. The primer-probe system of the real-time PCR was targeted against nor-1, a gene of the aflatoxin biosynthetic pathway. By application of this method the nor-1 transcription was quantified during the course of incubation. After 4 days of incubation nor-1 mRNA could be detected for the first time. The amount of nor-1 mRNA increased rapidly, and the maximum was achieved after 6 days. Then, starting very slowly, the mRNA was degraded until day 8, and this was followed by a very fast degradation, reaching nondetectable levels at days 9 and 10. First traces of aflatoxin B(1) could be detected between the 5th and 6th day of incubation. The aflatoxin concentration reached its maximum after 9 days of incubation and remained constant for the whole period of observation. To ensure that differences in the nor-1 mRNA concentration were due to different expression levels, the expression of the constitutively expressed β-tubulin gene (benA56) has also been monitored. The expression of benA56 remained constant during the whole incubation time. As a parameter for fungal growth, the number of nor-1 gene copies was determined during the course of incubation. The numbers of nor-1 gene copies increased at the beginning of the incubation and reached a plateau at day 5. They correlate well with the viable counts albeit at a higher level.

L10 ANSWER 5 OF 11 EMBASE on STN

ACCESSION NUMBER: 2003042480 EMBASE
TITLE: Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation.
AUTHOR: Yusuf R.Z.; Duan Z.; Lamendola D.E.; Penson R.T.; Seiden M.V.
CORPORATE SOURCE: M.V. Seiden, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, United States. mseiden@partners.org
SOURCE: Current Cancer Drug Targets, (2003) Vol. 3, No. 1, pp. 1-19.
Refs: 185
ISSN: 1568-0096 CODEN: CCDTB
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20030207
Last Updated on STN: 20030207

AB It has been approximately ten years since the **Food** and Drug Administration (FDA) approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma. Since the approval, the drug has found therapeutic applications in a variety of schedules and in a wide variety of epithelial malignancies. Its novel mechanism of action provided the hope that it would demonstrate anti-neoplastic activity in multidrug resistant tumor cells. Unfortunately, as with

other chemotherapeutic drugs, resistance is commonly seen. Laboratory investigation has defined a wide variety of resistance mechanisms including overexpression of multidrug resistance (MDR-1) gene, molecular changes in the target molecule (β-tubulin), changes in apoptotic regulatory and mitosis checkpoint proteins, and more recently changes in lipid composition and potentially the overexpression of interleukin 6 (IL-6). This review describes the in vitro molecular data that define and support the various mechanisms of resistance and critically evaluates the evidence for the participation of these mechanisms in clinically relevant paclitaxel resistance. This review also explores pharmacologic attempts to modulate paclitaxel resistance, principally through inhibition of the MDR-1 drug efflux pump. Future avenues for drug resistance research and its pharmacologic manipulation in the clinic are discussed.

L10 ANSWER 6 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2002330599 EMBASE
TITLE: PC-SPES inhibits colon cancer growth in vitro and in vivo.
AUTHOR: Huerta S.; Arteaga J.R.; Irwin R.W.; Ikezoe T.; Heber D.; Koeffler H.P.
CORPORATE SOURCE: S. Huerta, UCLA Center for Human Nutrition, 12-217 Warren Hall, 900 Veteran Avenue, Los Angeles, CA 90095, United States. shuerta@pol.net
SOURCE: Cancer Research, (15 Sep 2002) Vol. 62, No. 18, pp. 5204-5209.
Refs: 37
ISSN: 0008-5472 CODEN: CNREA8
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20021010
Last Updated on STN: 20021010

AB PC-SPES is a mixture of eight herbs with antiproliferative activity in prostate cancer cell lines and antitumor effects in animal models of prostate cancer. In addition, evidence of clinical efficacy in advanced prostate cancer has been reported. PC-SPES has also been shown to have antitumor activity against several other cancer cell lines including breast and neuroepithelial cancer, melanoma, and leukemia cell lines. Because of these findings, we investigated the effects of PC-SPES in vitro in colon cancer cell lines SW480, SW620, and DLD-1 and in vivo in the Apc(min) mouse, a murine model for intestinal carcinogenesis. For the in vitro studies, colon cancer cell lines were exposed to an ethanolic extract of PC-SPES compared with a diluent control [ethanol ≤ 0.3% (v/v)]. PC-SPES resulted in a marked suppression of cell proliferation in all colon cancer cells studied. PC-SPES (3 μl/ml) caused a 95% inhibition of cell proliferation of the DLD-1 colon cancer cell line, and similar results were observed in the SW480 and SW620 colon cancer cell lines. Cell cycle analysis demonstrated a drastic (≥60%) accumulation of cells in the G(2)-M phase with a comitant decrease of cells in the G(0)-G(1) phase in all colon cancer cell lines studied after treatment with PC-SPES (1.5 μl/ml for 48 h). Western blot analysis demonstrated a decrease in protein levels of β-tubulin in the SW620 cell line exposed to PC-SPES. Terminal deoxynucleotidyl

transferase-mediated nick end labeling analysis revealed an increase in apoptotic colon cancer cells incubated with PC-SPES. For the in vivo studies, female 4-5-week-old Apc(min) mice were randomized to two groups: a PC-SPES-treated group (n = 11) received 250 mg/kg/day (0.2 ml) PC-SPES via gastrointestinal gavage; and a control group (n = 10) received 0.2 ml of the vehicle solution (1.5% carboxymethylcellulose with 0.2% Tween 20) via gastrointestinal gavage. Both groups were treated five times a week for 10 weeks. After treatment, the gastrointestinal tract was dissected for polyp scoring by two observers blinded to treatment. The Apc(min) mice given PC-SPES had a 58% reduction in tumor number and a 56% decrease in tumor load. No effect on either **food** intake or body weight was observed in the treated versus sham groups. The present study is the first to report the potent activity of PC-SPES against colon cancer. Both cell cycle arrest and apoptosis occurred after treatment with PC-SPES. This suggests that the components of this herbal mixture, either independently or in combination, acted in colon cancer, resulting in a drastic effect on tumor initiation and tumor progression.

L10 ANSWER 7 OF 11 EMBASE on STN

ACCESSION NUMBER: 2003019447 EMBASE
TITLE: Taxanes for advanced non-small cell lung cancer.
AUTHOR: Ramalingam S.; Belani C.P.
CORPORATE SOURCE: S. Ramalingam, Lung Cancer Program, Univ. of Pittsburgh Sch. of Medicine, 5150 Centre Ave., Pittsburgh, PA 15232, United States. Belanicp@msx.upmc.edu
SOURCE: Expert Opinion on Pharmacotherapy, (1 Dec 2002) Vol. 3, No. 12, pp. 1693-1709.
Refs: 113
ISSN: 1465-6566 CODEN: EOPHF7
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20030129
Last Updated on STN: 20030129

AB The emergence of novel chemotherapeutic agents with promising anticancer activity in non-small cell lung cancer (NSCLC) during the 1990s has led to an expanded role for chemotherapy in the management of this disease. The taxanes (paclitaxel and docetaxel) are novel microtubule stabilising agents, and have become an integral part of several commonly-used chemotherapy regimens in NSCLC. Taxanes inhibit the growth of lung cancer cell lines, exhibit synergistic interaction with other chemotherapy agents and enhance the efficacy of radiation in vitro. When used in low doses (metronomic dosing), they have important antiangiogenic properties. Several Phase II and III clinical trials have established the efficacy of the taxanes, as single agents and when used in combination with a platinum compound, in the treatment of advanced NSCLC. The use of a taxane in combination with a platinum compound has become an acceptable standard for patients with advanced or metastatic NSCLC. In addition to its efficacy in the first-line therapy of NSCLC, docetaxel is also the

FDA-approved second-line agent for recurrent or relapsed NSCLC in the US. Several ongoing trials are comparing the efficacy of combining molecularly targeted agents with taxane-based regimens for the treatment of advanced NSCLC.

L10 ANSWER 8 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 1999280035 EMBASE
TITLE: Molecular tools for identification of Penicillium starter cultures used in the **food** industry.
AUTHOR: Dupont J.; Magnin S.; Marti A.; Brousse M.
CORPORATE SOURCE: J. Dupont, Museum National Histoire Naturelle, Inst. Systematique CNRS FR 1541, Laboratoire Cryptogamie, 12 Rue Buffon, 75005 Paris, France. jdupont@mnhn.fr
SOURCE: International Journal of Food Microbiology, (1999) Vol. 49, No. 3, pp. 109-118.
Refs: 31
ISSN: 0168-1605 CODEN: IJFMDD
PUBLISHER IDENT.: S 0168-1605(99)00055-0
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19990826
Last Updated on STN: 19990826

AB The main goal of this work was to develop rapid and accurate molecular tools to discriminate species of white industrial Penicillia. We applied three different polymerase chain reaction (PCR) based techniques. Sequences of the ITS region of the rRNA gene unit and of the 5' end of the β tubulin gene yielded 1.2% and 5.8% nucleotide variability respectively, between Penicillium camembertii and Penicillium nalgiovense. Polymorphic restriction sites were found in both sequences. These may be used in diagnostic PCR-RFLP analysis to rapidly distinguish between the two Penicillium species. Random amplified polymorphic DNA (RAPD) markers were also useful to differentiate these two species, but no polymorphism was found at the subspecific level, which evidenced a high level of homogeneity of the isolates studied. By means of these three techniques, the real identity of industrial strains of Penicillium chrysogenum and P. nalgiovense could be demonstrated. The comparison of these isolates with type strains of the two species suggested that the former corresponds to P. nalgiovense. The genetic relatedness between P. naglovense and Penicillium dipodomyis was also confirmed.

L10 ANSWER 9 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 1998295966 EMBASE
TITLE: Molecular phylogenetic, morphological, and mycotoxin data support reidentification of the Quorn mycoprotein fungus as Fusarium venenatum.
AUTHOR: O'Donnell K.; Cigelnik E.; Casper H.H.
CORPORATE SOURCE: K. O'Donnell, Microbial Properties Research, Natl. Ctr. Agr. Utilization Res., USDA-ARS, Peoria, IL 61604, United States
SOURCE: Fungal Genetics and Biology, (1998) Vol. 23, No. 1, pp. 57-67.

Refs: 31
ISSN: 1087-1845 CODEN: FGBIFV
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Molecular phylogenetic, morphological, and mycotoxin data were obtained in order to investigate the relationships and identity of the Quorn mycoprotein fungus within Fusarium and to examine Quorn strains and commercial Quorn **food** products for trichothecene mycotoxins. Phylogenetic analyses of aligned DNA sequences obtained via the polymerase chain reaction from the nuclear 28S ribosomal DNA, nuclear ribosomal internal transcribed spacer region, and β-tubulin gene exons and introns indicate that the Quorn fungus is Fusarium venenatum, rather than F. graminearum as previously reported. All of the Quorn strains examined were morphologically degenerate aconidial colonial mutants except for NRRL 25139, which produced chlamydospores in recurved terminal chains together with mostly 5-septate sporodochial conidia on doliform monophialides diagnostic of F. venenatum. Bootstrap and decay analyses provide strong support for a monophyletic lineage containing F. venenatum and several other type A trichothecene-producing species, while reference strains of F. graminearum were nested in a separate clade of species that produce type B trichothecenes and/or zearalenone. Analysis of mycotoxins from rice cultures inoculated with Quorn strain NRRL 25416 revealed that four type A trichothecenes are produced, but at low levels relative to strain NRRL 22198 of F. venenatum. No trichothecene mycotoxins, however, were detected from the analysis of three commercial Quorn products marketed for human consumption in England.

L10 ANSWER 10 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 96233362 EMBASE
DOCUMENT NUMBER: 1996233362
TITLE: Genetic analysis of the Drosophila β3-tubulin gene demonstrates that the microtubule cytoskeleton in the cells of the visceral mesoderm is required for morphogenesis of the midgut endoderm.
AUTHOR: Dettman R.W.; Turner F.R.; Raff E.C.
CORPORATE SOURCE: Department of Biology, Jordan Hall, Indiana University,Bloomington, IN 47405, United States
SOURCE: Developmental Biology, (1996) Vol. 177, No. 1, pp. 117-135.
ISSN: 0012-1606 CODEN: DEBIAO
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 021 Developmental Biology and Teratology
022 Human Genetics
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 960821
Last Updated on STN: 960821

AB We have investigated the cellular basis for lethality of mutant alleles of the Drosophila melanogaster β3-tubulin gene, βTub60D. Lethal β3 mutations can be grouped into two classes: the most severe mutations (Class I alleles) cause death during the first larval instar, while weaker alleles (Class II) cause

death in later larval stages or in early pupal development. Since β3 is not expressed during larval development, lethality of the Class I mutations must reflect essential functions of β3 in embryogenesis. β3-tubulin is zygotically expressed during midembryogenesis in the developing mesoderm, and the major site of β3 accumulation is in the developing muscles during myogenesis. We show that the embryonic pattern of β3 expression, including accumulation in the developing musculature, is conserved in other Drosophila species. However, we found that loss of β3 function does not cause discernible defects in either the ultrastructure or function of the larval muscle. Thus β3-tubulin is dispensable in its highest site of accumulation. Rather, the essential site of function of β3 in embryos is in cells of the visceral mesoderm. Lethality of Class I alleles is caused by defects in midgut morphogenesis and failure of gut function. Although the folding pattern is irregular and the gut is smaller than normal, a complete folded gut forms in mutant larvae, and the visceral muscle functions normally to move **food** through the gut. However, mutant larvae cannot absorb nutrients across the gut wall. Thus loss of β3 function in the mesoderm results in defects in the underlying endodermally derived layer of the gut. Our data provide an assay for cellular interactions between mesoderm and endodermal tissues and reveal a role for the microtubule cytoskeleton of the visceral mesodermal cells in differentiation of the endodermal cell layer of the larval gut.

L10 ANSWER 11 OF 11 EMBASE on STN

ACCESSION NUMBER: 93314967 EMBASE
DOCUMENT NUMBER: 1993314967
TITLE: HgEDTA complex inhbitis GTP interactions with the E-site of brain β-tubulin.
AUTHOR: Duhr E.F.; Pendergrass J.C.; Slevin J.T.; Haley B.E.
CORPORATE SOURCE: Div. Medicinal Chemistry/Pharmaceut., College of Pharmacy, University of Kentucky Med. Center,Lexington, KY 40536-0093, United States
SOURCE: Toxicology and Applied Pharmacology, (1993) Vol. 122, No. 2, pp. 273-280.
ISSN: 0041-008X CODEN: TXAPA
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 008 Neurology and Neurosurgery
029 Clinical Biochemistry
052 Toxicology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 931205
Last Updated on STN: 931205

AB We have found that EDTA and EGTA complexes of Hg2+, which conventional wisdom has assumed are biologically inert, are potentially injurious to the neuronal cytoskeleton. Tubulin, a major protein component of the neuronal cytoskeleton, is the target of multiple toxicants, including many heavy metal ions. Among the mercurials, inorganic mercuric ion (Hg2+) is one of the most potent inhibitors of microtubule polymerization both in vivo and in vitro. In contrast to other heavy metals, the capacity of Hg2+ to inhibit microtubule polymerization or disrupt formed microtubules cannot be prevented by the addition of EDTA and EGTA, both of which bind Hg2+ with very high

affinity. To the contrary, the addition of these two chelating agents potentiates Hg2+ inhibition of tubulin polymerization. Results herein show that HgEDTA and HgEGTA inhibit tubulin polymerization by disrupting the interaction of GTP with the E-site of brain β-tubulin, an obligatory step in the polymerization of tubulin. Both HgEDTA and HgEGTA, but not free Hg2+, prevented binding of [32P]8N3GTP, a photoaffinity nucleotide analog of GTP, to the E-site and displaced bound [32P]8N3GTP at low micromolar concentrations. This complete inhibition of photoinsertion into the E-site occurred in a concentration- and time-dependent fashion and was specific for Hg2+ complexes of EDTA and EGTA, among the chelating agents tested. Given the ubiquity of Hg2+ in the environment and the widespread use of EDTA in **foodstuffs** and medicine, these mercury complexes may pose a potentially serious threat to human health and play a role in diseases of the neuronal cytoskeleton.

FILE 'HOME' ENTERED AT 08:42:11 ON 22 JUL 2005

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number 155567

TO: Andrew D Kosar **Art Unit:** 1654 **Location:** rem/3C04/3C18 **Serial Number:** 10/766480 **Friday, July 22, 2005**	**From:** Beverly Shears **Location:** Biotech-Chem Library REM 1A54 **Phone:** 571-272-2528 beverly.shears@uspto.gov

Search Notes

Protein Sequence Searches – February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.

- If you encounter an accession number from an older search run against UniProt (results file extension **.rup**) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (uniPARC) at:

  http://www.pir.uniprot.org/database/archive.shtml

If you have any questions regarding this information or your results, please contact any STIC searcher.

STIC-Biotech/ChemLib CRF 159567 mg

From: Kosar, Andrew 80341
Sent: Saturday, July 16, 2005 12:04 PM
To: STIC-Biotech/ChemLib
Subject: sequence search 10/766,480

Please search SEQ ID NOs: 1 and 2 in 10/766,480
please do interference search as well.
thank you.

Andrew D. Kosar, Ph.D.
Patent Examiner
Art Unit 1654
(571)272-0913
Office REMSEN 3C04
Mail REMSEN 3C18

1 aa 7
2 aa 20

mg

7/18/05

Date completed: _____
Searcher: Beverly e2528
Terminal time: _____
Elapsed time: _____
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
_____ STIC
_____ CM-1
_____ Pre-S

Type of Search
_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure
_____ Bibliographic

Vendors
_____ IG
_____ STN
_____ Dialog
_____ APS
_____ Geninfo
_____ SDC
_____ DARC/Questel
✓ Other (EIC)

1590 (9-90)

```
=> d his ful

     (FILE 'HOME' ENTERED AT 08:10:12 ON 22 JUL 2005)
               DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 08:11:58 ON 22 JUL 2005
L1          1669 SEA ABB=ON  PLU=ON  NMVPFPR|ASAFQGIGSTHWVYDGVGNS/SQSP

     FILE 'CAPLUS' ENTERED AT 08:12:24 ON 22 JUL 2005
L2           303 SEA ABB=ON  PLU=ON  L1
L3             9 SEA ABB=ON  PLU=ON  L2 AND ((NUTRITION? OR DIET?)(S)SUPPLEM
               ENT? OR FOOD? OR FEED?)
L*** DEL       0 S L3 AND MOESSLER ?/AU
L*** DEL       0 S L2 AND MOESSLER ?/AU
L*** DEL       0 S (MOESSLER H? AND (RIEDL C? OR SCHNAIT ?))/AU
               D 1-9 .BEVSTR
               SEL HIT L3 1-9 RN
               D QUE L3

     FILE 'REGISTRY' ENTERED AT 08:15:34 ON 22 JUL 2005
L4            31 SEA ABB=ON  PLU=ON  (588739-86-0/BI OR 688816-39-9/BI OR
               688820-97-5/BI OR 688821-07-0/BI OR 688822-60-8/BI OR
               694539-54-3/BI OR 694543-35-6/BI OR 694548-37-3/BI OR
               694548-48-6/BI OR 694548-90-8/BI OR 694551-10-5/BI OR
               694552-91-5/BI OR 696667-25-1/BI OR 696671-14-4/BI OR
               696671-21-3/BI OR 696672-44-3/BI OR 696673-43-5/BI OR
               701312-15-4/BI OR 701987-88-4/BI OR 701988-13-8/BI OR
               702715-26-2/BI OR 702718-15-8/BI OR 702718-46-5/BI OR
               845186-43-8/BI OR 845188-05-8/BI OR 845189-45-9/BI OR
               845221-36-5/BI OR 845222-98-2/BI OR 845224-38-6/BI OR
               847721-13-5/BI OR 855561-06-7/BI)
               D QUE
L5            31 SEA ABB=ON  PLU=ON  L1 AND L4
               D L5 1-31 .BEVREG1

     FILE 'MEDLINE, BIOSIS, EMBASE, FSTA, NUTRACEUT' ENTERED AT 08:16:09
     ON 22 JUL 2005
L*** DEL    1767 S L1

     FILE 'FSTA' ENTERED AT 08:16:25 ON 22 JUL 2005
L*** DEL       0 S L1

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:16:47 ON 22 JUL 2005
L6          1767 SEA ABB=ON  PLU=ON  L1
L7            20 SEA ABB=ON  PLU=ON  L6 AND ((NUTRITION? OR DIET?)(S)
               SUPPLEMENT? OR FOOD? OR FEED?)
L8            20 DUP REM L7 (0 DUPLICATES REMOVED)
               D 1-20 IBIB ABS

     FILE 'HOME' ENTERED AT 08:17:23 ON 22 JUL 2005
               D COST

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:41:30 ON 22 JUL 2005
L9            11 SEA ABB=ON  PLU=ON  L6 AND ((NUTRITION? OR DIET?)(S)
               SUPPLEMENT? OR FOOD OR FOODSTUFF OR FEED OR FEEDSTUFF)
L10           11 DUP REM L9 (0 DUPLICATES REMOVED)
               D 1-11 IBIB ABS

     FILE 'HOME' ENTERED AT 08:42:11 ON 22 JUL 2005
```

Searcher : Shears 571-272-2528

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:42:43 ON 22 JUL 2005

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8
DICTIONARY FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMI for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storin of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2005 VOL 143 ISS 5
FILE LAST UPDATED: 21 Jul 2005 (20050721/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MEDLINE
FILE LAST UPDATED: 21 JUL 2005 (20050721/UP). FILE COVERS 1950 TO DA

On December 19, 2004, the 2005 MeSH terms were loaded.

Searcher : Shears 571-272-2528

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 21 July 2005 (20050721/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE
FILE COVERS 1974 TO 21 Jul 2005 (20050721/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE FSTA
FILE LAST UPDATED: 18 JUL 2005 <20050718/UP>
FILE COVERS 1969 TO DATE.

FILE NUTRACEUT
FILE LAST UPDATED: 29 JUN 2005 <20050629/UP>
FILE COVERS MAY 1996 TO DATE

FILE HOME

=>